EU Commission: Strategy Paper with Measures against Medicine Supply Shortages
The European Commission has adopted a package of measures to prevent and mitigate shortages of critical medicines in the EU this coming winter, next winter and beyond. The reform of the pharmaceutical legislation, announced in April 2023, includes a package of measures aimed at increasing long-term security of supply or managing medicine shortages. The "set of actions" now presented complements the reform of the pharmaceutical law.
The most important planned measures are:
- Establishment of a voluntary EU solidarity mechanism
- A Union list of critical medicines
- Regulatory flexibility
- EU guidelines for the procurement of medicines in the interest of greater security of supply
- Joint procurement at EU level of antibiotics and respiratory virus treatments
Furthermore, the Commission plans to set up a "Critical Medicines Alliance", which should become operational in early 2024. This alliance will focus on a specific number of critical medicines where the risk of shortages is highest and the impact on health systems is greatest. Among the actions it will take are:
- Coordinating public procurement procedures at EU level
- Exploring opportunities to diversify global supply chains through strategic partnerships
- Coordinated strengthening of Europe's capacity to produce critical medicines and their ingredients and to innovate in the manufacturing sector
- Developing a common strategic approach to stockpiling medicines in the EU
- To support the mobilisation and alignment of EU and national resources
To strengthen the resilience of the supply chain, the Commission will thus network with international partners. Strategic partnerships with third countries will also be launched with regard to the production of critical medicines.
Source: EU Commission press release
Related GMP News
02.10.2024MHRA: New Rules for Manufacturers and Wholesalers after Brexit
24.09.2024What is RCA (Root Cause Analysis)?
18.09.2024Lack of GMP Training and related Documentation: What Deviations can be found in FDA Warning Letters?
04.09.2024Switzerland: Changes for the Qualification of QPs (Responsible Person; RP in Switzerland)
04.09.2024Insufficient Root Cause Analysis leads to FDA Warning Letter
28.08.2024Switzerland to implement Measures to combat Shortages of Medicines